APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
APPENDICES. A systematic review and economic model of the ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Core symptoms Educational performance Quality <strong>of</strong> life Adverse events<br />
Global efficacy (parent): % rated<br />
good or excellent<br />
OROS: 54.0%<br />
IR: 46.5%<br />
Placebo: 20.3%<br />
*p < 0.05 compared with placebo; no significant<br />
differences between OROS <strong>and</strong> IR-MPH<br />
Overall treatment effect F(2,233) = 16.40,<br />
p < 0.001<br />
SNAP-IV Hyperactivity/Impulsivity (teacher rated)<br />
Mean (SD), OROS MPH/IR-MPH/placebo<br />
Baseline (n = 274): 1.60 (0.9)/1.62 (0.8)/1.00 (0.8)<br />
End <strong>of</strong> study (n = 236): 0.96* (0.79)/0.93*<br />
(0.79)/1.57 (0.89)<br />
*p < 0.05 compared with placebo; no significant<br />
differences between OROS <strong>and</strong> IR-MPH<br />
Overall treatment effect F(2,233) = 4.23,<br />
p < 0.001<br />
SNAP-IV Inattention (parent rated)<br />
Mean (SD), OROS MPH/IR-MPH/placebo<br />
Baseline (n = 276): 2.29 (0.5)/2.16 (0.6)/2.18 (0.5)<br />
End <strong>of</strong> study (n = 250): 1.38* (0.68)/1.39*<br />
(0.73)/2.00 (0.78)<br />
*p < 0.05 compared with placebo; no significant<br />
differences between OROS <strong>and</strong> IR-MPH<br />
Overall treatment effect F(2,247) = 19.15,<br />
p < 0.001<br />
© Queen’s Printer <strong>and</strong> Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
Health Technology Assessment 2006; Vol. 10: No. 23<br />
SNAP-IV Hyperactive/impulsivity (parent rated)<br />
Mean (SD), OROS MPH/IR-MPH/placebo<br />
Baseline (n = 276): 2.02 (0.6)/1.84 (0.7)/1.99 (0.7)<br />
End <strong>of</strong> study (n = 250): 1.11* (0.65)/1.10*<br />
(0.69)/1.83 (0.89)<br />
*p < 0.05 compared with placebo; no significant<br />
differences between OROS <strong>and</strong> IR-MPH<br />
Overall treatment effect F(2,248) = 24.79,<br />
p < 0.001<br />
Conclusions Authors’ conclusions: For <strong>the</strong> treatment <strong>of</strong> core ADHD symptoms, OROS MPH dose once daily <strong>and</strong> IR-MPH dose t.d.s. were<br />
superior to placebo <strong>and</strong> were not significantly different from each o<strong>the</strong>r<br />
Reviewer’s comments: No comments noted<br />
359